论文部分内容阅读
用湖南鼻咽癌细胞株HNI2为免疫原,制备了数株抗鼻咽癌单抗(Abl).再用两株Abl(FC_2、HNI-5)为免疫原,制备了两株抗独特型单抗Ab2(2H4和5D3).体外和体内实验证实,2H4、5D3能替代鼻咽癌抗原,诱导体液和细胞免疫应答.因而认为它们可以作为新型抗鼻咽癌疫苗的候选物.选择19例晚期鼻咽癌病人用氢氧化铝凝胶沉淀的Ab2(Alum-2H4、Alum5D3),配合放疗进行主动免疫治疗;9例单纯接受放疗的晚期鼻咽癌病人作为对照组.经血清学检测发现,治疗组病人的抗抗独特型抗体(Ab3)、抗肿瘤抗体(Ab1’)水平均有不同程度增高,但也产生了人抗鼠抗体(HAMA).血清细胞因子TNF-α、IFN-γ、IL-2水平在大多数治疗组病人中升高,而对照组Ab1 TNF-α、IFN-γIFM及IL-2血清水平均未升高.初步临床研究显示,鼠源性抗独特型单抗用于临床治疗是安全的,且Ab2能模拟肿瘤相关抗原,激发机体产生主动免疫应答.
Several strains of anti-nasopharynx cancer monoclonal antibody (Abl) were prepared using the Hunan nasopharyngeal carcinoma cell line HNI2 as an immunogen. Two Abl (FC-2, HNI-5) were used as immunogens to prepare two anti-idiotypes. Anti-Ab2 (2H4 and 5D3). In vitro and in vivo experiments confirmed that 2H4, 5D3 can replace nasopharyngeal carcinoma antigens, induce humoral and cellular immune responses. Therefore, they can be considered as new anti-nasopharyngeal cancer vaccine candidates. 19 cases of advanced selection Patients with nasopharyngeal carcinoma were treated with Ab2 (Alum-2H4, Alum5D3) precipitated with aluminum hydroxide gel, and active immunotherapy was performed with radiotherapy; 9 patients with advanced nasopharyngeal carcinoma who received radiotherapy alone were used as a control group. The levels of anti-anti-idiotypic antibody (Ab3) and anti-tumor antibody (Ab1’) in patients in the group increased to varying degrees, but also produced human anti-mouse antibody (HAMA). Serum cytokines TNF-α, IFN-γ, IL Levels of -2 increased in most treatment groups, whereas Ab1 TNF-α, IFN-γ IFM, and IL-2 serum levels did not increase in the control group. Preliminary clinical studies have shown that mouse-derived anti-idiotype monoclonal antibodies are used Clinical treatment is safe, and Ab2 can simulate tumor-associated antigens and stimulate the body to produce active immune responses.